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Mice with mutations in the gene encoding Fas ligand
(FasL) develop lymphoproliferation and systemic au-
toimmune diseases. However, the cellular subset re-
sponsible for the prevention of autoimmunity in FasL-
deficient mice remains undetermined. Here, we show
that mice with FasL loss on either B or T cells had
identical life span as littermates, and both genotypes
developed signs of autoimmunity. In addition, we
show that T cell-dependent death was vital for the
elimination of aberrant T cells and for controlling the
numbers of B cells and dendritic cells that dampen
autoimmune responses. Furthermore, we show that
the loss of FasL on T cells affected the follicular den-
tritic cell network in the germinal centers, leading to
an impaired recall response to exogenous antigen.
These results disclose the distinct roles of cellular
subsets in FasL-dependent control of autoimmunity
and provide further insight into the role of FasL in
humoral immunity.
INTRODUCTION
Apoptosis is critical to the development and homeostasis of the
immune system. It involves intrinsic and extrinsic pathways
mediated respectively by the Bcl2 protein family (Strasser et al.,
2000) and death receptor ligands including FasL. Cell death has
to be tightly controlled because an excess of apoptosis can result
in degenerative diseases (Honig and Rosenberg, 2000), whereas
a lack of apoptosis underlies cancer and autoimmunity, as is illus-
trated by the observation of lymphoproliferation and systemic
autoimmunity in mice carrying the lpr (lymphoproliferation) or
gld (generalized lymphoproliferative disorder) natural mutations
of the Fas- or FasL-encoding genes, respectively (Adachi et al.,
1996; Cohen and Eisenberg, 1991; Karray et al., 2004), as well
as by the Fas mutations observed in humans with lymphoprolifer-
ative diseases (Fisher et al., 1995; Rieux-Laucat et al., 1995).
In contrast to the widespread expression of Fas, FasL is
predominantly expressed on activated T and natural killer cells922 Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc.(Nagata and Golstein, 1995). Yet although FasL expression is
tightly regulated in the immune system, the cellular basis of the
lymphoproliferative syndrome is not well understood. T cells
clearly play a critical role, because lymphoproliferation
involves a peculiar type of T cell population, whose phenotype
is CD3+B220+CD4CD8, and because it is prevented by thy-
mectomy (Steinberg et al., 1980). In addition, with systemic loss
of FasL expression, it is difficult to identify the role of each cellular
subset in autoimmunity. Earlier studies showed that transgenic
restoration of Fas expression by T cells in lpr mice rescued the
mice from lymphoproliferation but not autoimmunity (Fukuyama
et al., 1998), whereas deletion of B cells from lpr mice led to re-
duced T cell proliferation (Shlomchik et al., 1994). Finally, recent
studies involving tissue-specific loss of Fas demonstrated that, in
addition to T and B cells, antigen-presenting cells (APCs) are also
involved in the development of lymphoproliferation and the
autoimmune syndrome (Hao et al., 2004; Stranges et al., 2007).
During the immune response to a T cell-dependent antigen, B
cells are activated by interaction with APCs and T cells, and form
germinal centers (GCs) within a network of follicular dendritic
cells (FDCs) in the follicle of peripheral lymphoid tissues (Kelsoe,
1996; Liu et al., 1991). Although there is ample evidence docu-
menting the role of the Bcl2 protein family in regulating B cell re-
sponses (Strasser, 2005), the exact role of FasL-mediated death
remains uncertain and even controversial. Evidence indicates
that, in vitro, activated B cells are sensitive to Fas-mediated
death (Daniel and Krammer, 1994). In addition, GC B cells are
Fas positive and can be rescued from apoptosis in vitro through
stimulation with either the antigen receptor or CD40 (Lagresle
et al., 1995; Smith et al., 1995), suggesting that the Fas pathway
is involved in clonal selection within the GCs. Additional evi-
dence supporting a role for Fas in B cell responses includes the
observation that B cells with the lpr mutation are required for full
development of the lpr autoimmune phenotype, suggesting
a role for Fas in either establishing or maintaining B cell tolerance
(Eisenberg et al., 1994). However, in vivo studies on the role of
Fas-mediated death in T cell-dependent humoral immune re-
sponses led to conflicting results. Whereas one study pointed
to a normal GC reaction in immunized lpr mice, another study
demonstrated that the establishment of the memory B cell reper-
toire is abnormal in immunized lpr mice (Smith et al., 1995;
Takahashi et al., 2001).
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FasL on T and B Cells Controls AutoimmunityIn order to further elucidate the issue of FasL-mediated signal-
ing in controlling cell expansion, autoimmunity, and the T cell-
dependent humoral response, we deleted the Fasl gene through
Cre-mediated recombination (Karray et al., 2004) in T, B, and
myeloid cells. We found that FasL on T or B cells controls auto-
immunity, and that its function in T cells is critical for maintaining
an adequate population of APC subsets to prevent autoimmunity
and to generate a recall response to a foreign antigen.
RESULTS
Specific Inactivation of FasL in T Lymphocytes
Resulted in Lymphadenopathy
To understand the role of the Fas-FasL pathway in regulating
normal immune response and autoimmunity, we used mice
with selective FasL loss in T cells, B cells, or myeloid cells
(CD11b+Gr1+). Faslfl/fl mice, in which the Fasl gene is flanked by
two LoxP sites (Karray et al., 2004), were crossed to mice ex-
pressing Cre recombinase under the control of the proximal lck
promoter (resulting in a deletion in all T cells, T-Fasl/ mice)
(Hennet et al., 1995), under the control of the CD19 promoter (re-
sulting in a deletion in B cells, B-Fasl/) (Rickert et al., 1997), or
under the control of lysozyme M gene (resulting in a deletion in
myeloid cells, namely macrophages and neutrophils, M-Fasl/)
(Clausen et al., 1999).
In mice from the three genotypes, FasL mRNA expression was
highly reduced in thymocytes, splenocytes, and bone marrow
cells from T-Fasl/ mice, B-Fasl/ mice, and M-Fasl/ mice,
respectively, thereby confirming an efficient Cre-mediated
recombination (Figure 1A). Further PCR analyses demonstrated
that purified T cells, B cells, and bone marrow CD11b+Gr1+ cells
from the respective gene-targeted mice carried deleted Fasl
alleles, whereas the floxed allele was almost absent (Figure 1A,
samples 2, 9, and 13). In T-Fasl/ mice, lymph node (LN) cells
and splenocytes carried both floxed and deleted Fasl alleles,
indicating that the Fasl gene was deleted in secondary lymphoid
organs (Figure 1A, samples 3 and 5). Moreover, PCR analysis of
lymphoid cells that were not targeted by Fasl gene mutation or
non-lymphoid tissues demonstrated that the Cre-mediated re-
combination is tissue specific (Figure 1A, samples 4, 6, 10 and
12). In addition, FACS analysis of FasL on the surface and intra-
cellularly confirmed the absence of its expression on activated
T cells, B cells, and myeloid cells in the respective gene-targeted
mice (Figure 1B and Figure S1A available online). Membrane ex-
pression of FasL was detected on anti-CD3 activated T cells and
LPS-activated B cells in control mice, whereas intracellular FasL
expression was detected only in activated T cells (Figures 1B
and 1C). We could not detect FasL expression on LPS-activated
bone marrow cells from controls (Figure S1A), despite the in-
crease of CD11b expression. Moreover, FasL expression was
not detected in resting B and T cells (data not shown).
In contrast to most FasL-deficient mice that died by 6 months
of age (Karray et al., 2004), mice with FasL loss on T cells, B cells,
or myeloid cells demonstrated no physical abnormality at all
ages; their weight and life span were identical to those of control
littermates, and they are fertile (data not shown). Interestingly,
only mice with FasL loss on T cells developed a phenotype char-
acterized by lymphadenopathy over time, as was illustrated by
their increased size compared to FasL-sufficient littermates orto mice with FasL loss on B cells or myeloid cells (Figure S1B). Re-
markably, the lymphadenopathy in T-Fasl/ mice was less pro-
nounced than in age-matched FasL-deficient mice (Figure S1B).
Moreover, cell quantification supported the macroscopic data in
that there was a substantial increase in the absolute number of
total cells in LNs from 7- to 9-month-old T-Fasl/ mice com-
pared to controls (Figure 2A; p % 0.02) or B-Fasl/ mice and
M-Fasl/ mice (Figure 2G). However, the cell-count increase
remained lower than in age-matched Fasl/ mice (Figure 2A;
p < 0.0001).
In contrast to FasL-deficient mice, which develop splenomeg-
aly, the spleens from mice that lack FasL on T, B, or myeloid cells
were approximately the same size as the spleens from control
littermates (Figure S1B). In addition, gross analysis of thymi
from control and T-Fasl/ mice revealed no difference in size
at all ages. FACS analysis of thymocytes showed that the pro-
portion of single-positive CD4+CD8, CD8+CD4, and double-
positive CD4+CD8+ thymocytes was similar in 5-month-old
T-Fasl/ mice and control littermates, reinforcing the hypothe-
sis that FasL function is dispensable for normal thymocyte devel-
opment (Figure S1C). Taken together, these results indicated
that FasL on T cells is important for LN sizing.
FasL on T Cells Is Required for the Control of Abnormal
TCellDevelopmentandforLN-ResidentCellHomeostasis
The hallmark of FasL-deficient mice is the development and
expansion in peripheral lymphoid organs of the
CD3+B220+CD4CD8 abnormal T cell population (Karray
et al., 2004). The number of CD3+B220+CD4CD8 abnormal
T cells in the LNs of 5-month-old T-Fasl/ mice was lower
than in age-matched Fasl/ mice (Figure 2B; p = 0.003). This
abnormal population did not develop in control littermates or
upon inactivation of the Fasl gene in B cells or myeloid cells (Fig-
ures 2B and 2G), indicating that this population originates from
T cells.
The analysis of conventional cell populations from LNs of
T-Fasl/ mice demonstrated an amplification of the CD19+
cell population at all ages compared to littermates (Figure 2C;
p < 0.03). The total number of CD8+ and CD4+ T cells from
T-Fasl/ mice was identical to controls at 5 months of age, but
lower than in age-matched Fasl/ mice (Figures 2D and 2E; p <
0.009). However, by 9 months of age, the number of CD4+ T cells
was increased compared to littermates (Figure 2E; p = 0.002).
The CD8+ T cell numbers, which significantly enhanced from 5
to 9 months of age (Figure 2D; p = 0.013), remained nonetheless
similar in T-Fasl/ mice and control mice. As for mice that bear
the lpr or gld mutation (Cohen and Eisenberg, 1991), the number
of normal lymphoid cells was decreased in T-Fasl/ mice that
were more than 9 months of age. In contrast, the total LN cell
number did not change in mice with FasL loss on B or myeloid
cells as the mice got older (Figure 2F). In addition, CD4+ T cell,
CD8+ T cell, and CD19+ B cell distributions in LNs from 7-
month-old B-Fasl/ mice or M-Fasl/ mice were identical to
those in control mice (Figure 2G). These findings point to the piv-
otal role of FasL on T cells in eliminating CD3+B220+CD4CD8
aberrant T cells and in preserving the number of B cells in the
LNs.
Immunohistological analysis of FasL-deficient mice LNs
revealed a hyperplasic tissue characterized by the absence ofImmunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc. 923
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FasL on T and B Cells Controls AutoimmunityFigure 1. Efficient and Specific Cre-Mediated Fasl/ Gene Deletion
(A) Cell-specific deletion of Fasl gene. Q-RT-PCR and classical PCR were performed on cells from control mice, from Fasl/ mice, and from mice with FasL loss
on T cells, B cells, or myeloid cells. FasL mRNA expression was normalized to control littermates. Numbers correspond to tissues used for both Q-RT-PCR and
PCR and are as follows: for T-Fasl/ mice, 1 = thymocytes, 2 = purified T cells, 3 = LN cells, 4 = T cell-depleted splenocytes, 5 = splenocytes, and 6 = tail tissue;
for B-Fasl/ mice, 8 = splenocytes, 9 = purified B cells, and 10 = tail tissue; for M-Fasl/ mice 11 = bone marrow cells, 12 = tail tissue, and 13 = CD11b+Gr1+
purified bone marrow cells; and 7 = tissue from FasL-deficient mice. Results shown represent mean ± SEM and are from one representative experiment out of
two (n = 2–3 mice per genotype). ***p < 0.0001 for thymocytes versus splenocytes in TFasl/ mice; p = 0.078 and p = 0.08 are respectively for B-Fasl/ and
M-Fasl/ tissues as compared to Fasl/ tissues.
(B and C) FACS analysis of surface and intracellular FasL expression on control activated T cells, B cells, and respective gene-targeted mice. Purified T cells (B)
and B cells (C) were respectively activated with CD3 antibody (5 mg/ml) and 10 mg/ml of LPS for 24 hr. Plots are from one representative experiment out of three
(n = 2–3 mice per genotype).follicles (Figure 2H), whereas LNs from mice with FasL loss in
T cells have follicles with distorted organization. Interestingly,
despite their regular size and cell number, LNs from mice with
FasL loss in B cells or myeloid cells still displayed a partially
disorganized structure (Figure 2H). Quantitative analysis of
Ki67 staining in T-Fasl/ mice revealed a 2-fold increase of
Ki67-positive cells over control littermates, as well as over
B-Fasl/ and M-Fasl/ mice (Figure 2I). Moreover, in contrast
924 Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc.
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FasL on T and B Cells Controls AutoimmunityFigure 2. FasL Is Required for the Abnormal T Cell Development and the Homeostasis of LN-Resident Cells
(A–E) Increased cell number in T-Fasl/ mice.
(A) LN cell counts at indicated age from littermates (n = 5), T-Fasl/ mice (n = 5), and Fasl/ mice (n = 4) were 3.38 ± 1.173 106, 8.9 ± 2.33 3 106, and 294.5 ±
34.26 3 106, respectively. *p = 0.02 and **p = 0.002 as compared to littermates. ***p < 0.0001 as compared to Fasl/ mice.
(B) Characteristic CD3+B220+CD8CD4 cells from TFasl/ mice (n = 5), littermates (n = 5) and Fasl/ mice (n = 4) were quantified by flow cytometry after stain-
ing with CD3 and B220 antibodies. Results shown represent cellularity ± SEM. *p = 0.014 as compared to littermates, **p = 0.003 as compared to Fasl/ mice.
(C–E) Conventional B cell (C), CD8+ T cell (D), and CD4+ T cell (E) numbers were determined by staining with CD19 and a mixture of CD4 and CD8 antibodies,
respectively. Results shown represent cellularity ± SEM. For CD19+ B cells, *p% 0.03 and ***p = 0.0003 as compared to littermates; **p = 0.0022 as compared to
Fasl/ mice. For CD8+ T cells, *p = 0.013 for 5-month-old T-Fasl/ mice versus 9 month-old T-Fasl/ mice, and **p = 0.003 as compared to Fasl/ mice. For
CD4+ T cells, **p = 0.0086 for 5-month-old T-Fasl/ mice versus age-matched Fasl/ mice; **p = 0.0028 for 9-month-old T-Fasl/ mice versus age matched
littermates, and ***p = 0.0005 for 5-month-old T-Fasl/ mice versus 9-month-old T-Fasl/ mice.
(F and G) Normal cell distribution in B-Fasl/ mice and M-Fasl/ mice. Absolute number of total cells (four to six mice per genotype) from axillary LNs isolated
from B-Fasl/ mice, M-Fasl/ mice, and littermates at 5 months of age were 3.160 ± 0.33 3 106; 4.30 ± 0.86 3 106 and 3.38 ± 1.14 3 106, respectively (F);
conventional T cells and B cells as well as abnormal CD3+B220+CD4CD8 in B-Fasl/ mice, M-Fasl/ mice, and littermates at 7 months of age (G). Results
shown represent cellularity ± SEM.
(H). Histological analysis of LNs from mice at 5 months of age. Fixed sections were stained with hematoxylin + eosin + saffranin or Ki67 antibody for proliferating
cells. Scale bars represent 100 mm.
(I) Quantification of Ki67+ cells was determined from three mice per group and control littermates were considered to be the reference point.Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc. 925
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FasL on T and B Cells Controls AutoimmunityFigure 3. DC Accumulation in T-Fasl/ Mice
(A and B) Spleen cellularity in T-Fasl/ mice and Fasl/ mice at indicated ages (A) and in 5- to 7-month-old B-Fasl/ mice and M-Fasl/ mice (B). Number of
total spleen cells of T-Fasl/ mice (n = 6–7), Fasl/ mice (n = 4), B-Fasl/ mice (n = 5), M-Fasl/ mice (n = 5), and littermates (n = 6–7) were 87.33 ± 8.383 106,
242 ± 14.27 3 106, 87.75 ± 6.39 3 106, 81.25 ± 8.53 3 106, and 78.43 ± 5.12 3 106, respectively. ***p < 0.0001 as compared to Fasl/ mice.
(C and D) Increased CD11c cell numbers. In (C), splenocytes were stained for different markers and numbers in the quadrant indicate percentage of high CD11c+I-
Ab+ cells; plots are from a representative experiment out of three independent experiments (n = 2 per genotype for each experiment). As shown in (D), numbers of
CD11chiand CD11clo were determined from (C). Results shown represent mean ± SEM. **p% 0.0074 for T-Fasl/ mice versus Fasl/ mice or littermates and
***p% 0.0009 for T-Fasl/ mice versus Fasl/ mice.to Ki67 staining being mostly localized in GCs of the B-Fasl/
and M-Fasl/ mice, Ki67-positive cells in T-Fasl/ mice are
spread diffusely throughout the tissue (Figure 2H). Ki67 staining
combined with the increased size of LNs in Fasl/ mice demon-
strated that cells are accumulating. Thus, FasL on lymphocytes
or myeloid cells is important for LN-structure establishment.
Extended Life Span of Splenic CD11c Dendritic Cells in
T-Fasl/ Mice
In contrast to LNs, spleens from mice that lack FasL on T cells
were identical at all ages in terms of size and total cell counts
to control littermates (Figure S1B and Figure 3A), B-Fasl/
mice, or M-Fasl/ mice (Figure 3B). In Fasl/ mice, total spleen
cell count (255 ± 5.83 106) was increased by 2.9-fold compared
to that in T-Fasl/ spleen (87.33 ± 8.383 106) at 3–5 months of
age (Figure 3A; p < 0.0001). However, cell-distribution analysis
identified increasing numbers of CD11chi dendritic cells (DCs)
as mice aged (Figures 3C and 3D). Indeed, spleens from young
T-Fasl/ mice showed an identical number of CD11chi DCs
compared to littermates, but by 9 months of age, the CD11chi926 Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc.DC number was two-fold greater compared to littermates
(Figure 3D; p = 0.0088). Conversely, in FasL-deficient mice, an
expansion of CD11chi DCs was obvious at 4 months of age
and was higher at 9 months than in age-matched T-Fasl/
mice (Figure 3D; p = 0.0074). Unexpectedly, the CD11clo DCs
expanded more in the spleen from both genotypes (Figures 3C
and 3D; p % 0.0007), whereas spleens from control mice dis-
played identical number of CD11c DCs at all ages (Figure 3D).
These results indicated that FasL on T cells is critical for
maintaining the size of CD11c DCs.
Analysis of B and T lymphocyte distributions in the spleen re-
vealed a decrease in the number of CD8+ T cells in 5-month-old
T-Fasl/ mice compared to littermates (Figure 4A; p = 0.002).
This reduced number is counterbalanced by the presence of
abnormal CD3+B220+CD8CD4 T cells (Figure 4B), and such
a finding is in agreement with previous work showing that these
abnormal T cells arise from CD8+ T cells (Pestano et al., 1999).
Furthermore, both CD8+ T cell and abnormal T cell numbers
were higher in the spleen from Fasl/ mice than from age-
matched T-Fasl/ mice (Figures 4A and 4B; p% 0.005). CD4+
Immunity
FasL on T and B Cells Controls AutoimmunityFigure 4. Reduced Number of CD8+ T Cells in the Spleen of T-Fasl/ Mice
(A and B) Number of CD8+ T cells and abnormal CD3+B220+CD4CD8 cells were determined by flow-cytometry analysis. Results shown represent cellularity ±
SEM (n = 4–7 mice for each genotype). *p = 0.002 as compared to littermates. **p < 0.005, and ***p < 0.0001 as compared to Fasl/ mice.
(C–E) Conventional CD4+, CD19+, and CD8+ cells from spleens were numbered at the indicated ages in T-Fasl/ mice and Fasl/ mice (C and D), and at
7 months of age in B-Fasl/ mice and M-Fasl/ mice (E). Results shown represent cellularity ± SEM (n = 4–5 mice per genotype). *p = 0.025 for B-Fasl/
mice versus littermates, **p% 0.001 for T-Fasl/ mice versus Fasl/ mice or littermates, and ***p = 0.0004 for T-Fasl/ mice versus Fasl/ mice.
(F) Disorganized spleen architecture in the absence of splenomegaly. Spleens from 5-month-old littermates, T-Fasl/ mice, B-Fasl/ mice, M-Fasl/ mice, and
Fasl/ mice were fixed and sections were stained with hematoxylin + eosin + saffranin. Scale bars represent 100 mm.T and CD19+ B cell numbers were substantially lower than in
Fasl/ mice but similar to those of littermates (Figures 4C and
4D; p < 0.001).
FasL deletion in B or myeloid cells did not result in major
changes in B or T cell distribution, except a slight increase in
CD4+ cell population from 7-month-old B-Fasl/ mice
(Figure 4E; p = 0.025). Interestingly, although the size was normal,
the architecture of the spleens from T-Fasl/ mice, B-Fasl/
mice, and M-Fasl/ mice was disorganized but in a less signifi-
cant manner than in the hyperplasic Fasl/ spleen. In the former,
follicles have irregular sizes and numbers resulting in a reduced
amount of red pulp (Figure 4F). It is worth noting that mice with
FasL loss on T cells showed the most disorganized follicle struc-
ture compared to T-Fasl/ or M-Fasl/ mice. These results in-
dicated that FasL on cells from both innate and adaptive immune
compartments is needed for maintaining spleen architecture.
FasL-Negative T Cells Displayed Activated Phenotype
but Normal Response to TCR Stimulation
Further examination of CD4+ T cells and CD8+ T cells in the
spleen from T-Fasl/ mice revealed that the majority of thesecells displayed an activated-memory phenotype. Splenic
T cells from control littermates at 5 months of age contained
populations of CD44lo and CD44hi T cells, with the majority being
CD44loCD62Lhi naive cells. These results contrast with T-Fasl/
mice in which the majority of CD44+ cells were skewed toward
CD44hiCD62lo activated-memory phenotype (Figure 5A). Fur-
thermore, the increased expression of Fas and TRAIL (tumor
necrosis factor-related apoptosis-inducing ligand) receptors
(DR5) (Figure 5B), and reduced expression of the KLF2 transcrip-
tion factor (Figure 5C), supported the enhanced activation phe-
notype of T cells lacking FasL. In normal tissues, Fas expression
is constitutive, whereas TRAIL-receptor expression is induced; it
has been reported that KLF2, which functions to prevent sponta-
neous activation (Kuo et al., 1997), is highly expressed in thymo-
cytes and peripheral resting T cells. Results depicted in Figure 5C
showed that thymocytes from mice of both genotypes showed
identical KLF2 expression but that KLF2 expression was dramat-
ically decreased in CD4+ T cells from T-Fasl/ mice compared
to CD4+ T cells from control mice. With such an activated pheno-
type, one would expect that the T cell response in mice lacking
FasL expression on T cells would exceed the response inImmunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc. 927
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FasL on T and B Cells Controls AutoimmunityFigure 5. Activated Phenotype of FasL-Deficient T Cells
(A) Analysis of CD62L and CD44 expression gated on splenic CD4+ T and CD8+ T cells so that the proportion of naive versus activated and memory cells could be
determined. Plots are from a representative experiment; mice were 5 months old (n = 3 per group).
(B) Fas and DR5 expression on cell-sorted splenic CD4+ T and CD8+ T cells from 5-month-old mice (n = 4 per group). All plots are from a representative
experiment.
(C) Analysis of KLF2 mRNA expression in thymocytes and purified splenic CD4+ T cells. Mice were 4 months old T-Fasl/ (n = 5) and littermates (n = 3). Data
represent mean ± SEM from three independent experiments.
(D) T cell proliferation response. Purified T cells from 5-month-old T-Fasl/ mice (n = 4), littermates (n = 4), and Fasl/ mice (n = 2) were stimulated with coated
CD3 antibody for 3 days. Results shown represent mean ± SEM. *p = 0.034 as compared to Fasl/ mice.
(E) CD44, CD62L, Fas, and DR5 expression was determined on gated splenic CD11b+ cells and CD19+ cells from M-Fasl/ mice and B-Fasl/ mice,
respectively.littermate mice. Therefore, we assessed the ability of T cells
to respond to activation through TCR, ex vivo. Unexpectedly,
purified T cells from T-Fasl/ mice in comparison to control
mice displayed a reduced (although not significant) amount of
H3-thymidine incorporation in response to activation with CD3
antibody, whereas T cells from FasL-deficient mice showed an
enhanced response to TCR stimulation (Figure 5D; p = 0.034).
FasL-defective myeloid cells (CD11b+Gr1+) displayed a pheno-
type characteristic of resting cells because expression levels of
CD44, CD62L, Fas, and DR5 were similar to FasL-proficient cells
(Figure 5E), whereas FasL-deficient B cells showed a slight
increase of CD44 and Fas expression. Taken together, these re-
sults indicated that FasL-deficient T cells acquired an activated
phenotype without gaining survival advantage.
FasL on T and B Cells Is Required to Prevent from
Systemic Autoimmunity
One of the consequences of dysregulated lymphocyte apoptosis
is the development of autoimmunity. Circulating autoantibodies
against a variety of self-antigens were detected in animals with
deficiency of Fasl (Cohen and Eisenberg, 1991; Karray et al.,928 Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc.2004), Fas (Andrews et al., 1978), and Bcl2 genes (Bouillet
et al., 1999). Therefore, we examined whether FasL deficiency
in T, B, or myeloid cells might lead to the development of IgG
to double-stranded DNA (dsDNA). Both females and males
from 5 to 12–13 months of age contained circulating anti-dsDNA
IgG compared to controls, with the highest autoantibody titers
observed in the sera of mice that were more than 7 months of
age. Remarkably, the autoantibody titers in T-Fasl/ mice
remained lower than in age-matched Fasl/ mice, indicating
that other cell types contribute to the development of the
enhanced systemic autoimmunity observed in FasL-deficient
mice (Figure 6A; p % 0.0099). Indeed, FasL loss on B cells led
also to the production of circulating anti-dsDNA IgG in the sera
of B-Fasl/ mice that were more than 7 months of age (Fig-
ure 6A; p% 0.05). No circulating autoantibodies were detected
in the sera of M-Fasl/ mice (Figure 6A). The production of
autoantibodies was accompanied by a slight increase in IgG2a
and IgG2b in the sera of T-Fasl/ mice (Figure 6B; p % 0.05),
whereas the amounts of both IgM and IgG subclasses were
significantly increased in Fasl / mice (Figure 6B; p% 0.05) as
already demonstrated (Karray et al., 2004). Mice lacking FasL
Immunity
FasL on T and B Cells Controls AutoimmunityFigure 6. FasL-Dependent Autoimmunity
(A) Sera from mice that lack FasL on T cells, B cells, or myeloid cells and from age-matched control mice were analyzed for anti-dsDNA IgG. T-Fasl/ mice were
aged from 5 to more than 9 months (5-month-old mice, n = 3; 7-month-old mice, n = 5; 9-month-old mice, n = 5; and >9-month-old mice, n = 4); B-Fasl/ mice
were 7 to 9 months old (n = 8); M-Fasl/ mice were more than 7 months of age (n = 6) and Fasl/ mice were from 7 to 12 months of age (n = 6). *p% 0.05 for
littermates versus T-Fasl/ mice or B-Fasl/ mice, and **p% 0.0099 as compared to Fasl/ mice.
(B and C) IgG subclasses and IgM concentrations in the sera from 7- to 9-month-old T-Fasl/mice (n = 8–10), Fasl/ mice (n = 5), and littermates (n = 8–10) (B), or
7-month-old B-Fasl/ mice and M-Fasl/ mice (n = 7–10) (C). *p < 0.05, **p < 0.005, and ***p% 0.0002.
(D) Kidney histological analysis. Kidney from 7- to 9-month-old littermates, T-Fasl/ mice, B-Fasl/ mice, M-Fasl/ mice, and FasL-deficient mice were fixed,
and sections were stained with hematoxylin + eosin + saffranin. Scale bars represent 100 mm.on B cells or myeloid cells showed decreased IgG3 and
enhanced IgG2a sera titers, respectively, compared to control
littermates (Figure 6C; p < 0.05). Another feature of the autoim-
mune syndrome in FasL-deficient mice is the presence of
lymphoid infiltrates and immune complexes in the kidney (Karray
et al., 2004). Hematoxylin and eosin staining of fixed kidney
sections from 9-month-old T-Fasl/ mice showed normal kid-
ney morphology similar to that seen in age matched controls
or in 7-month-old B-Fasl/ or M-Fasl/ mice (Figure 6D). As
expected, kidney sections from Fasl/ mice presented histolog-
ical abnormalities characterized by glomerular hyalinization.
Taken together, these results underline the importance of FasL
expression by T and B cells to prevent autoimmunity.
Defective T Cell-Dependent Recall Response
in T-Fasl/ Mice
To address whether the FasL-mediated effect on B cells and DCs
contributes to the regulation of immune response, we immunized
T-Fasl/ mice with OVA, a T cell-dependent antigen, and chal-
lenged them at day seven. Two weeks after secondary immuniza-
tion, sera were tested for OVA-specific IgG1 antibodies. Quanti-
fication by ELISA of sera from immunized mice showed a low
production of OVA-specific IgG1 antibody in mice that lack
FasL on T cells compared to control littermates, B-Fasl/
mice, or M-Fasl/ mice (Figure 7A; p = 0.005). Moreover, the
response of OVA-stimulated CD4+ T cells from T-Fasl/ was
dramatically decreased, as revealed by the weak production of
IFN-g (Figure 7B; p = 0.019). Similar results were obtained withOVA-stimulated splenocytes (Figure S2). OVA-specific IgM
responses were identical in mice from all genotypes at D14 after
primary immunization (Figure 7C). Next, we assessed GC forma-
tion, the anatomical hallmark of ongoing T-B cell cooperation
(MacLennan, 1994), in frozen spleen sections from T-Fasl/
and control littermates by staining with peanut agglutinin (PNA).
As shown in Figure 7D, PNA staining was apparent in spleen sec-
tions from both genotypes, but more restricted labeling was seen
in spleen sections from T-Fasl/ mice. Defects in GC response
can be manifested by changes in GC size, frequency and/or orga-
nization (Allen et al., 2007). GCs contain, in addition to B and
T cells, a network of FDCs that sequester antigens (Tew et al.,
2001). To assess the FDC network, we colabeled frozen spleen
sections from immunized mice with antibodies to CD35 and to
B220. In spleen sections from littermates and mice that lack
FasL on B cells or myeloid cells, GCs showed strong, enriched,
and overlapping staining for CD35+ FDCs and for B220+ B cells,
whereas in T-Fasl/ mice, the CD35+ FDC staining is extended
throughout the GCs (Figure 7E). The disturbed FDC network in
T-Fasl/ mice was not associated with the absence of ICAM-1
expression (data not shown), which is critical for the establish-
ment of a firm contact between FDCs and activated B cells
(Freedman et al., 1990). In T-Fasl/ mice, further examination
of the B220 and CD35 staining showed irregularly sized follicles,
and surface quantification revealed a reduced ratio of surface
follicle to total surface in these sections (Figure 7F). These results
point to the role of FasL on T cells in regulating secondary IgG
response to antigen challenge.Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc. 929
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T-Fasl/ mice, B-Fasl/ mice, M-Fasl/ mice, and littermates were immunized with OVA-CFA (50 mg) and challenged with OVA-IFA (50 mg) at day 7. Mice were
analyzed 1 week and 2 weeks after secondary immunization for OVA-IgM and OVA-IgG1, respectively. Data are from three independent experiments for T-Fasl/
mice and two independent experiments for both B-Fasl/ mice and M-Fasl/ mice (six mice per genotype for each experiment).
(A) Sera level of OVA-specific IgG1 antibodies. *p = 0.005 for T-Fasl/ mice as compared to littermates.
(B) Purified splenic CD4+ T cells from TFasl/ mice were restimulated with OVA (100 mg/ml) for 90 hr, and IFN-g secretion was detected in the supernatants by
ELISA. Results shown represent the amount of cytokine ± SEM. *p = 0.019 as compared to controls.
(C) Sera titer of OVA-specific IgM was determined at day 14 after primary immunization.
(D) Immunohistochemistry of spleen follicles from immunized T-Fasl/ and littermates for GC identification in cryostat sections stained with PNA.
(E) Cryostat sections from littermates, T-Fasl/ mice, B-Fasl/ mice, and M-Fasl/ mice were stained with CD35 and CD45R antibodies to show FDC and B
cells, respectively. For (D) and (E), each image is representative of spleen sections from two mice in two independent experiments. Scale bars represent respec-
tively 30 mm in (D) and in the top panel of (E) and 100 mm in the lower panel of (E). Results represent mean ± SEM.
(F) Ratio of surface follicles to total surface was quantified as described in the Experimental Procedures.DISCUSSION
Autoimmune manifestations, such as circulating autoantibodies,
were detected in mice and humans with defects in FasL-medi-
ated apoptosis pathways (Cohen and Eisenberg, 1991; Karray
et al., 2004; Rieux-Laucat et al., 1995). However, the cellular
target for the FasL-mediated effect, which might prevent autoim-
munity, has been less clear. Here, by selectively deleting the
Fasl gene in T cells, we showed that APC subsets and T cell pop-
ulations contribute to FasL-dependent regulation of autoimmu-
nity. B cells have dual roles, in that they function both as
effector cells producing antibodies and also as an APC subset,930 Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc.a function that is probably enhanced in an autoimmune setting
because of more efficient presentation of antigen via B cell-re-
ceptor-mediated endocytosis. In this setting, the predominant
B cell accumulation seen in T-Fasl/ mice underlies the need
for FasL expression by T cells to eliminate B cells that serve as
APCs, thus sustaining the survival of autoreactive FasL-deficient
T cells and producing autoantibodies. Similarly, professional
APCs (i.e., DCs), accumulated in mice that lack FasL on T cells,
but not in as pronounced a way as did B lymphocytes, indicating
that FasL is probably not the only regulator of DC loss. DCs from
perforin-deficient mice have been shown to be resistant to T cell-
mediated death (Yang et al., 2006). Moreover, the cellular target
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FasL on T and B Cells Controls Autoimmunityor timing for FasL- or perforin-mediated death of DCs could be
different. In this respect, it is worth noting that DC accumulation
in T-Fasl/ mice occurred over time and, interestingly, that the
CD11clo population is the predominant accumulating subset in
both T-Fasl/ and Fasl/ mice. Our results, which demonstrate
the critical role of FasL expression by T cells in eliminating APCs
specific to autoantigen in order to prevent the onset of autoim-
mune diseases, reinforce the observation of autoimmune syn-
drome in mice with Fas deficiency in B cells or DCs (Hao et al.,
2004; Stranges et al., 2007) or by transgenic overexpression of
a caspase inhibitor in DCs (Chen et al., 2006).
T-Fasl/ mice developed mild autoimmune syndrome
compared to Fasl/ mice (Karray et al., 2004), suggesting that
FasL deficiencies in different cell types are likely to be additive.
Indeed, mice with FasL deficiency on B cells displayed circulat-
ing autoantibodies, but how FasL on B cells prevents from
autoimmunity remains unclear. Activated B cells express Fas
(Liu et al., 1991) and in autoimmune setting they upregulate
FasL expression (Bonardelle et al., 2005). It is tempting, then,
to speculate that B cell-autonomous death may operate as an
additional mechanism to eliminate residual autoreactive B cells
that had escaped T cell-mediated death.
The lack of FasL on neutrophils and macrophages did not lead
to the development of autoimmune signs. These cells play a
pivotal role in the pathogenesis of other types of autoimmune
diseases such as inflammatory arthritis (Jonsson et al., 2005;
Ma et al., 2004). Recent studies demonstrated that FasL block-
ade was able to promote neutrophil survival, thereby enhancing
inflammation (Jonsson et al., 2005). Therefore, FasL-mediated
inflammation is likely to be dependent on the cell lineage and
inflammatory milieu.
FasL-deficient mice displayed splenomegaly and lymphade-
nopathy that were characterized by the development of abnor-
mal T cells and the accumulation of all immune cell types (Karray
et al., 2004 and unpublished data). A deficiency of FasL in T cells
led to the development of CD3+B220+CD4CD8 abnormal
T cells in lymphoid tissues. The fact that these abnormal
T cells do not arise when a deficiency of FasL (present work) or
Fas was targeted to other cell types, namely B cells, myeloid
cells, or DCs (Chen et al., 2006; Hao et al., 2004; Stranges
et al., 2007), sustains the T cell origin of these abnormal cells.
Moreover, their existence is strictly dependent on the Fas-FasL
pathway; mice deficient in other death-receptor signaling mole-
cules or in molecules implicated in the mitochondrial pathway,
such as Bim, do not develop these unusual T cells. However,
their numbers are dramatically increased in mice with deficiency
in both Fas and Bim, suggesting that the intrinsic apoptosis
pathway contributes to their homeostasis (Weant et al., 2008).
Interestingly, conventional T cells and B cells were accumulating
in the LNs but not in the spleen of these T-Fasl/ mice, demon-
strating that T cell-dependent death plays a major role in the size
of LNs. In the spleen, CD4+ T and CD8+ T cells that lack FasL
presented an enhanced activation phenotype indicating that
these cells have undergone activation by endogenous antigens
without gaining a survival advantage. These findings indicate
that FasL-mediated apoptosis is not the only mechanism that
downregulates chronically activated T cells. Enhanced TRAIL-
receptor expression by FasL-deficient T cells could be an alter-
native pathway along with TNFR and Bim, which regulate T cellhomeostasis. Moreover, our results are reminiscent of very re-
cent work in which a combined loss of Fas and Bim showed
that the Fas pathway is important in LN contraction, whereas
Bim functions by downsizing the response in the spleen (Hughes
et al., 2008; Weant et al., 2008). These results support a major
role for FasL on T cells in eliminating mainly chronically activated
autoreactive T cells and are in agreement with recently reported
results on the role of the Fas pathway in shutting down chronic
immune responses (Hao et al., 2004; Stranges et al., 2007).
Interestingly, the expanded cells in old mice with B cell-
specific FasL deficiency were T cells, suggesting that somehow
FasL on B cells is needed for the adjustment of the size of Fas-
FasL-proficient T cell population. Taken together, our data sug-
gest that the respective roles of FasL in conventional B and T cell
homeostasis are likely to be interdependent. Therefore, it will be
interesting to investigate whether a deficiency of FasL on B cells,
T cells, and myeloid cells will result in the full phenotype of FasL-
deficient mice.
GC B cells are Fas positive and are highly sensitive to FasL-
mediated apoptosis in vitro, raising the hypothesis that Fas is
involved in selection within the GC (Liu et al., 1991). Moreover,
very recent data by Hao et al. demonstrated that Fas expression
by GC B cells is essential for B and T cell homeostasis (Hao et al.,
2008). However, studies with lprmice led to conflicting results on
the role of Fas-mediated death in the generation of antigen-
specific responses (Smith et al., 1995; Takahashi et al., 2001).
In mice with FasL loss on T cells, although GC formation oc-
curred, a sustained IgG OVA-specific response was diminished.
The lack of response was not due to a defect in the B cell
compartment because we showed through FACS analysis that
splenocytes from T-Fasl/ mice displayed equal numbers of B
lymphocytes as littermates (data not shown). However, we
cannot rule out a defect in either B cell dynamics or organization
during the immune response. The development of a productive
GC response requires the formation of an FDC network to cap-
ture and hold antigen (Tew et al., 2001). In immunized T-Fasl/
mice, although ICAM-1 expression, necessary for the firm con-
tact between FDC and B cells, was normal, the FDC distribution
within the follicles was disturbed. This defect could have ham-
pered the efficiency of B cell signaling in response to antigen
engagement. In addition, the reduced number of follicles that
we observed could participate in an impaired recall response.
FDCs are a subset of DCs, and whether these cells are sensitive
to T cell-mediated death needs further investigation. Our present
data, describing a role for FasL in controlling humoral immune
response, are in agreement with the previous results on the
requirement of Fas-mediated death in the establishment of the
memory B cell repertoire (Takahashi et al., 2001).
In our study, FasL deficiency in T cells did not lead to a change
in animal life span or tissue damage as previously described in
mice with T cell-specific Fas loss (Hao et al., 2004). The reasons
for this discrepancy could be explained by the use of different
promoters that drive Cre expression in T cells, leading to the de-
letion of the Fas gene (CD4 promoter) or Fasl gene (lck promoter)
at different developmental stages in the two distinct experimen-
tal systems. The phenotype of our T-Fasl/ mice was found to
be similar to the phenotype of mice in which the Cre-mediated
Fas gene deletion in T cells was under the control of lck promoter
(Stranges et al., 2007).Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc. 931
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FasL on T and B Cells Controls AutoimmunityThe conclusion that emerges from our results is that the loss of
FasL by either B or T cells is sufficient to trigger the development
of autoimmune signs but not sufficient to reproduce the dramatic
phenotype of FasL-deficient mice. In addition, T cell-selective
death exercises a functional control on B cell and DC homeosta-
sis, thereby preventing the onset of systemic autoimmunity and
regulating overall humoral immunity.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice with Fasl gene bordered with two LoxP sites and FasL-deficient
mice were described earlier (Karray et al., 2004). Mice with Cre recombinase
controlled by the proximal lck promoter B6.Cg-TgLck-cre (Hennet et al.,
1995) were a generous gift from J.D. Marth (USA). Mice with Cre recombinase
under the control of the B6.CD19 promoter (Cre-CD19) (Clausen BE, 1999;
Rickert et al., 1997) and mice that express Cre recombinase in myeloid cells
(B6.Cre-LysM) (Clausen BE, 1999) were purchased from Artemis Pharmaceu-
tical Gmbh. All mice were genotyped by PCR with primers amplifying the lcK
Cre transgene (50-cggacgtccctgctcctggc-30 and 50-cctccctgttggagggtgtcg-
30 ), CD19-Cre transgene (50-gtaaactgggaggagtcag-30 and 50-cgaccggcaaacgg
acagaag-30), Cre-LysM transgene (50-atcgataccatggcaaggagtaagg-30 and 50-
ggatccgccgcataaccagtcaa-30), and Fasl generating ‘‘floxed’’ and null allele
products (Karray et al., 2004). Mice were housed at INSERM U580 and Institut
Gustave Roussy animal facilities under specific pathogen-free conditions,and
all experiments were performed according to the institutional and national
guidelines.
Lymphocyte and DC Preparation and Flow-Cytometric Analysis
DCs were prepared from collagenase-DNase-treated spleen, and lymphocyte
and thymocyte suspensions were prepared as previously described (Karray
et al., 2004). Labeled antibodies to FasL (clone MFL3), CD4, CD8, CD19,
CD35, CD44, CD45R/B220, CD62L, CD11c, Class II, DR5 (TRAIL receptor),
Fas, and Ig isotype controls were purchased from BD Biosciences PharMin-
gen. For all staining, cells were preincubated with Fc block (2.4G2). Flow-
cytometric data were acquired on FACSCalibur (Becton Dickinson), and
data analyses were performed with CellQuest software (Becton Dickinson).
CD4+ and CD8+ T cells were purified by cell sorting with a BD flow cytometer.
More than 95% of recovered cells were CD4 or CD8 positive. Total T cells from
spleen were purified with the mouse T lymphocyte enrichment set-DM (BD,
PharMingen). CD19+ B cells and CD11b+ myeloid cells were purified from
spleen and bone marrow respectively by negative selection with streptavidin
beads (BD, PharMingen), and more than 95% of recovered cells were
CD19+ or CD11b+. For FasL induction on T cells and B cells, cells were respec-
tively activated with CD3 antibodies and LPS for 24 hr.
ELISA for Immunoglobulins and Cytokines
Serum Igs were quantified with the Clonotyping System-AP (Southern
Biotechnology Associates). The dsDNA antibodies were detected with mouse
anti-dsDNA ELISA kit (Alpha Diagnostic International). Culture supernatants
were tested for IFN-g with an ELISA kit (eBiosciences). To measure OVA
antibodies, we applied sera from immunized mice at appropriate dilutions to
plates coated with 10 mg/ml of OVA, and then the plates were incubated
with AP-conjugated anti-mouse IgG1 or IgM (Southern Biotech).
In Vivo Immunization
Mice were immunized intraperitoneally with 50 mg of OVA (Sigma) emulsified in
complete Freund adjuvant (CFA), challenged on day 7 with 50 mg of OVA in
incomplete Freund adjuvant (IFA), and were killed 3 weeks after primary immu-
nization. Blood was collected on day 7, 14, and 21 after immunization, and
isotype-specific antibodies were quantified by ELISA.
T Cell Proliferation Assay and IFN-g Production
Purified T cells were cultured at 1 3 105 cells/well in round-bottom 96-well
plates coated with CD3 antibody (5 mg/ml) (clone 2C11, BD Biosciences, Phar-
Mingen) for 72 hr. Proliferation of T cells was determined by incorporation of
H3-thymidine for the last 12 hr of culture. For IFN-g production, purified CD4+932 Immunity 29, 922–933, December 19, 2008 ª2008 Elsevier Inc.T cells isolated on streptavidin beads (PharMingen) from spleens of immunized
mice at day 21 after primary immunization were stimulated with 100 mg/ml of
antigen, and culture supernatants were collected after 90 hr.
Histology and Immunohistochemistry
After prior fixation in FineFix (Milestone) and antigen retrieval with a citrate
buffer pH 6 at 98C, deparaffinized 4-mm-thick LN sections were incubated
with Ki67 antibody (Neomarkers, LabVision, Microm) and then with a Power
Vision HRP Kit, revealed by DAB, and counterstained by Mayer’s hematoxilin.
For spleen staining, cryostat sections were incubated with CD35 and CD45R-
B220 antibodies or peanut agglutinin (PNA,Vector Laboratory) and then with
a Power Vision HRP Kit and revealed by DAB. Ki67-positive cells or surface
follicles, identified with CD35-B220 labeling, were quantified and expressed
by the fractional area of stained cells within the node and spleen section,
respectively, and only the lymphoid tissue was compared to the whole surface.
This procedure was achieved with Pix-Cyt, a software package designed by
the Groupe Re´gional d’Etudes sur le Cancer, Centre Franc¸ois Baclesse,
Caen (P. Herlin and N. Elie). This system combines a dedicated slide scanner
and a computer-assisted image analysis.
Isolation of RNA and Quantitative RT-PCR
Total RNA was isolated from cells with Trizol (Sigma) and cDNA was synthe-
sized. PCR primers for KLF2 and FasL genes were designed by Applied
Biosystems and used according to the manufacturer’s recommendations.
The amount of sample RNA was normalized by the amplification of an endog-
enous control. We derived the relative quantification of the transcripts by using
the standard curve method (Applied Biosystems User Bulletin 2, ABI PRISM
7700 Sequence Detection System). Data were analyzed with the 2D DCt
method.
Statistical Analyses
Analyses of all data for significant differences were performed with unpaired
Student’s t test provided by GraphPad Prism 4. Data are presented as mean ±
SEM.
SUPPLEMENTAL DATA
Supplemental Data include two figures and can be found with this article online
at http://www.immunity.com/supplemental/S1074-7613(08)00475-5.
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